Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.
The company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate.
Research and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.
Immunovant shares fell 5% to trade at $33.76 on Thursday.
These analysts made changes to their …